The Protective Role of Phenolic Compounds Against Doxorubicin-induced Cardiotoxicity: A Comprehensive Review

References

• Bonadonna G, Monfardini S, De Lena M, Fossati-Bellani F, and Beretta G: Phase I and preliminary phase II evaluation of adriamycin (NSC 123127). Cancer Res 30(10), 2572–2582, 1970.
   PubMed Web of Science ®Google Scholar
• Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, et al.: Doxorubicin‐induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev 34(1), 106–135, 2014.
   PubMed Web of Science ®Google Scholar
• Villani F, Beretta G, and Guindani A: Evaluation of early doxorubicin-induced cardiotoxicity by means of systolic time intervals. Cancer Chemoth Pharm 3(4), 249–251, 1979.
   PubMed Web of Science ®Google Scholar
• Bristow M, Billingham M, Mason J, and Daniels J: Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62(6), 873–879, 1978.
   PubMedGoogle Scholar
• Pereira GC, Silva AM, Diogo CV, Carvalho FS, Monteiro P, et al.: Drug-induced cardiac mitochondrial toxicity and protection: from doxorubicin to carvedilol. Curr Pharm Des 17(20), 2113–2129, 2011.
   PubMed Web of Science ®Google Scholar
• Alexander J, Dainiak N, Berger HJ, Goldman L, Johnstone D, et al.: Serial assessment of doxorubicin cardiotoxicity with quantitative radionuclide angiocardiography. N Engl J Med 300(6), 278–283, 1979.
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Zhang J, Honbo N, and Karliner JS: Doxorubicin cardiomyopathy. Cardiology 115(2), 155–162, 2009.
   PubMed Web of Science ®Google Scholar
• Wallace KB: Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol 93(3), 105–115, 2003.
   PubMedGoogle Scholar
• Yeh ET, Tong AT, Lenihan DJ, Yusuf SW, Swafford J, et al.: Cardiovascular complications of cancer therapy diagnosis, pathogenesis, and management. Circulation 109(25), 3122–3131, 2004.
   PubMed Web of Science ®Google Scholar
• Childs AC, Phaneuf SL, Dirks AJ, Phillips T, and Leeuwenburgh C: Doxorubicin treatment in vivo causes cytochrome C release and cardiomyocyte apoptosis, as well as increased mitochondrial efficiency, superoxide dismutase activity, and Bcl-2: Bax ratio. Cancer Res 62(16), 4592–4598, 2002.
   PubMed Web of Science ®Google Scholar
• Pointon AV, Walker TM, Phillips KM, Luo J, Riley J, et al.: Doxorubicin in vivo rapidly alters expression and translation of myocardial electron transport chain genes, leads to ATP loss and caspase 3 activation. PLoS One 5(9), 12733, 2010.
   PubMed Web of Science ®Google Scholar
• Zhang S, Liu X, Bawa-Khalfe T, Lu L-S, Lyu YL, et al.: Identification of the molecular basis of doxorubicin-induced cardiotoxicity. Nature Med 18(11), 1639–1642, 2012.
   PubMed Web of Science ®Google Scholar
• Menna P, Recalcati S, Cairo G, and Minotti G: An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7(2), 80–85, 2007.
   PubMed Web of Science ®Google Scholar
• Raschi E, Vasina V, Ursino MG, Boriani G, Martoni A, et al.: Anticancer drugs and cardiotoxicity: insights and perspectives in the era of targeted therapy. Pharmacol Ther 125(2), 196–218, 2010.
   PubMed Web of Science ®Google Scholar
• Lebrecht D and Walker UA: Role of mtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol 7(2), 108–113, 2007.
   PubMed Web of Science ®Google Scholar
• Iarussi D, Indolfi P, Casale F, Coppolino P, Tedesco M, et al.: Recent advances in the prevention of anthracycline cardiotoxicity in childhood. Curr Med Chem 8(13), 1649–1660, 2001.
   PubMed Web of Science ®Google Scholar
• Takemura G and Fujiwara H: Doxorubicin-induced cardiomyopathy: from the cardiotoxic mechanisms to management. Prog Cardiovasc Dis 49(5), 330–352, 2007.
   PubMed Web of Science ®Google Scholar
• Xiao J, Sun GB, Sun B, Wu Y, He L, et al.: Kaempferol protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. Toxicology 292(1), 53–62, 2012.
   PubMed Web of Science ®Google Scholar
• Bravo L: Polyphenols: chemistry, dietary sources, metabolism, and nutritional significance. Nutr Rev 56(11), 317–333, 1998.
   PubMed Web of Science ®Google Scholar
• Soobrattee MA, Neergheen VS, Luximon-Ramma A, Aruoma OI, and Bahorun T: Phenolics as potential antioxidant therapeutic agents: mechanism and actions. Mutat Res Fund Mol Mech Mut 579(1), 200–213, 2005.
   PubMed Web of Science ®Google Scholar
• Williams RJ, Spencer JP, and Rice-Evans C: Flavonoids: antioxidants or signalling molecules? Free Rad Biol Med 36(7), 838–849, 2004.
   PubMed Web of Science ®Google Scholar
• Dai J and Mumper RJ: Plant phenolics: extraction, analysis and their antioxidant and anticancer properties. Molecules 15(10), 7313–7352, 2010.
   PubMed Web of Science ®Google Scholar
• Thilakarathna SH and Rupasinghe H: Flavonoid bioavailability and attempts for bioavailability enhancement. Nutrients 5(9), 3367–3387, 2013.
   PubMed Web of Science ®Google Scholar
• Lourenco CF, Gago B, Barbosa RM, de Freitas V, and Laranjinha J: LDL isolated from plasma-loaded red wine procyanidins resist lipid oxidation and tocopherol depletion. J Agric Food Chem 56(10), 3798–3804, 2008.
   PubMed Web of Science ®Google Scholar
• Thilakarathna SH, Wang Y, Rupasinghe H, and Ghanam K: Apple peel flavonoid-and triterpene-enriched extracts differentially affect cholesterol homeostasis in hamsters. J Funct Foods 4(4), 963–971, 2012.
   Web of Science ®Google Scholar
• Noll C, Hamelet J, Matulewicz E, Paul J-L, Delabar J-M, et al.: Effects of red wine polyphenolic compounds on paraoxonase-1 and lectin-like oxidized low-density lipoprotein receptor-1 in hyperhomocysteinemic mice. J Nutr Biochem 20(8), 586–596, 2009.
   PubMed Web of Science ®Google Scholar
• Peterson JJ, Dwyer JT, Jacques PF, and McCullough ML: Associations between flavonoids and cardiovascular disease incidence or mortality in European and US populations. Nutr Rev 70(9), 491–508, 2012.
   PubMed Web of Science ®Google Scholar
• Lapchak P, Maher P, Schubert D, and Zivin J: Baicalein, an antioxidant 12/15-lipoxygenase inhibitor improves clinical rating scores following multiple infarct embolic strokes. Neuroscience 150(3), 585–591, 2007.
   PubMed Web of Science ®Google Scholar
• Chen H-M, Hsu J-H, Liou S-F, Chen T-J, Chen L-Y, et al.: Baicalein, an active component of Scutellaria baicalensis Georgi, prevents lysophosphatidylcholine-induced cardiac injury by reducing reactive oxygen species production, calcium overload and apoptosis via MAPK pathways. BMC Complement Altern Med 14(1), 233, 2014.
   PubMed Web of Science ®Google Scholar
• Chang WT, Li J, Haung HH, Liu H, Han M, et al.: Baicalein protects against doxorubicin-induced cardiotoxicity by attenuation of mitochondrial oxidant injury and JNK activation. J Cell Biochem 112(10), 2873–2881, 2011.
   PubMed Web of Science ®Google Scholar
• Aroui S, Mili D, Brahim S, Waard MD, and Kenani A: Doxorubicin coupled to penetratin promotes apoptosis in CHO cells by a mechanism involving c-Jun NH2-terminal kinase. Biochem Biophys Res Commun 396(4), 908–914, 2010.
   PubMed Web of Science ®Google Scholar
• Yamamoto Y, Hoshino Y, Ito T, Nariai T, Mohri T, et al.: Atrogin-1 ubiquitin ligase is upregulated by doxorubicin via p38-MAP kinase in cardiac myocytes. Cardiovasc Res 79(1), 89–96, 2008.
   PubMed Web of Science ®Google Scholar
• Kalender S, Kalender Y, Ates A, Yel M, Olcay E, et al.: Protective role of antioxidant vitamin E and catechin on idarubicin-induced cardiotoxicity in rats. Braz J Med Biol Res 35(11), 1379–1387, 2002.
   PubMed Web of Science ®Google Scholar
• Kozluca O, Olcay E, Sürücü S, Güran Z, Kulaksiz T, et al.: Prevention of doxorubicin induced cardiotoxicity by catechin. Cancer Lett 99(1), 1–6, 1996.
   PubMed Web of Science ®Google Scholar
• Du Y and Lou H: Catechin and proanthocyanidin B4 from grape seeds prevent doxorubicin-induced toxicity in cardiomyocytes. Eur J Pharm 591(1), 96–101, 2008.
   PubMed Web of Science ®Google Scholar
• Li X, Huang Q, Ong C-N, Yang X-F, and Shen H-M: Chrysin sensitizes tumor necrosis factor-α-induced apoptosis in human tumor cells via suppression of nuclear factor-kappaB. Cancer Lett 293(1), 109–116, 2010.
   PubMed Web of Science ®Google Scholar
• Khoo BY, Chua SL, and Balaram P: Apoptotic effects of chrysin in human cancer cell lines. Int J Mol Sci 11(5), 2188–2199, 2010.
   PubMed Web of Science ®Google Scholar
• Cho H, Yun C-W, Park W-K, Kong J-Y, Kim KS, et al.: Modulation of the activity of pro-inflammatory enzymes, COX-2 and iNOS, by chrysin derivatives. Pharmacol Res 49(1), 37–43, 2004.
   PubMed Web of Science ®Google Scholar
• Pushpavalli G, Kalaiarasi P, Veeramani C, and Pugalendi KV: Effect of chrysin on hepatoprotective and antioxidant status in D-galactosamine-induced hepatitis in rats. Eur J Pharmacol 631(1), 36–41, 2010.
   PubMed Web of Science ®Google Scholar
• Mantawy EM, El-Bakly WM, Esmat A, Badr AM, and El-Demerdash E: Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Eur J Pharmacol 728, 107–118, 2014.
   PubMed Web of Science ®Google Scholar
• Yang Y, Zhou X, Xiao M, Hong Z, Gong Q, et al.: Discovery of chrysoeriol, a PI3K-AKT-mTOR pathway inhibitor with potent antitumor activity against human multiple myeloma cells in vitro. J Huazhong Univ Sci Technol Med Sci 30, 734–740, 2010.
   PubMed Web of Science ®Google Scholar
• Liu Z, Song X-D, Xin Y, Wang X-J, Yu H, et al.: Protective effect of chrysoeriol against doxorubicin-induced cardiotoxicity in vitro. Chin Med J (Engl) 122(21), 2652–2656, 2009.
   PubMed Web of Science ®Google Scholar
• Etcheverry SB, Ferrer EG, Naso L, Rivadeneira J, Salinas V, et al.: Antioxidant effects of the VO (IV) hesperidin complex and its role in cancer chemoprevention. JBIC J Biol Inorg Chem 13(3), 435–447, 2008.
   PubMed Web of Science ®Google Scholar
• Kalpana K, Srinivasan M, and Menon VP: Evaluation of antioxidant activity of hesperidin and its protective effect on H2O2 induced oxidative damage on pBR322 DNA and RBC cellular membrane. Mol Cell Biochem 323(1–2), 21–29, 2009.
   PubMed Web of Science ®Google Scholar
• Abdel-Raheem IT and Abdel-Ghany AA: Hesperidin alleviates doxorubicin-induced cardiotoxicity in rats. J Egypt Natl Canc Inst 21(2), 175–184, 2009.
   PubMedGoogle Scholar
• Hozayen WG and Seif HSA: Protective effects of rutin and hesperidin against doxorubicin-induced lipodystrophy and cardiotoxicity in albino rats. J Am Sci 7(12), 765–775, 2011.
   Google Scholar
• Ameer B, Weintraub RA, Johnson JV, Yost RA, and Rouseff RL: Flavanone absorption after naringin, hesperidin, and citrus administration. Clin Pharm Ther 60(1), 34–40, 1996.
   PubMed Web of Science ®Google Scholar
• Lee N-K, Choi S-H, Park S-H, Park E-K, and Kim D-H: Antiallergic activity of hesperidin is activated by intestinal microflora. Pharmacology 71(4), 174–180, 2004.
   PubMed Web of Science ®Google Scholar
• Trivedi P, Kushwaha S, Tripathi D, and Jena G: Cardioprotective effects of hesperetin against doxorubicin-induced oxidative stress and DNA damage in rat. Cardiovasc Toxicol 11(3), 215–225, 2011.
   PubMed Web of Science ®Google Scholar
• Zhao G, Duan J, Xie Y, Lin G, Luo H, et al.: Effects of solid dispersion and self-emulsifying formulations on the solubility, dissolution, permeability and pharmacokinetics of isorhamnetin, quercetin and kaempferol in total flavones of Hippophae rhamnoides L. Drug Dev Ind Pharm 39(7), 1037–1045, 2013.
   PubMed Web of Science ®Google Scholar
• Panda VS and Naik SR: Evaluation of cardioprotective activity of Ginkgo biloba and Ocimum sanctum in rodents. Altern Med Rev 14(2), 161, 2009.
   PubMedGoogle Scholar
• Han X, Gao S, Cheng Y, Sun Y, Liu W, et al.: Protective effect of naringenin-7-O-glucoside against oxidative stress induced by doxorubicin in H9c2 cardiomyocytes. Biosci Trends 6(1), 19–25, 2012.
   PubMed Web of Science ®Google Scholar
• Sun J, Sun G, Meng X, Wang H, Luo Y, et al.: Isorhamnetin protects against doxorubicin-induced cardiotoxicity in vivo and in vitro. PLoS One 8(5), e64526, 2013.
   PubMed Web of Science ®Google Scholar
• Morrison DK: MAP kinase pathways. Cold Spring Harb Perspect Biol 4(11), e11254, 2012.
   PubMed Web of Science ®Google Scholar
• Olszewska M: Separation of quercetin, sexangularetin, kaempferol and isorhamnetin for simultaneous HPLC determination of flavonoid aglycones in inflorescences, leaves and fruits of three< i>Sorbusspecies. J Pharm Biomed Anal 48(3), 629–635, 2008.
   PubMed Web of Science ®Google Scholar
• Keyhanian S and Stahl-Biskup E: Phenolic constituents in dried flowers of aloe vera (Aloe barbadensis) and their in vitro antioxidative capacity. Planta Med 73(06), 599–602, 2007.
   PubMed Web of Science ®Google Scholar
• Li N, Liu J-H, Zhang J, and Yu B-Y: Comparative evaluation of cytotoxicity and antioxidative activity of 20 flavonoids. J Agr Food Chem 56(10), 3876–3883, 2008.
   PubMed Web of Science ®Google Scholar
• Bhouri W, Bouhlel I, Boubaker J, Kilani S, Ghedira K, et al.: Induction of apoptosis in human lymphoblastoid cells by kaempferol 3-O-beta-isorhamninoside and rhamnocitrin 3-O-beta-isorhamninoside from Rhamnus alaternus L. (Rhamnaceae). Cell Prolif 44(3), 283–290, 2011.
   PubMed Web of Science ®Google Scholar
• Jang YJ, Kim J, Shim J, Kim J, Byun S, et al.: Kaempferol attenuates 4-hydroxynonenal-induced apoptosis in PC12 cells by directly inhibiting NADPH oxidase. J Pharmacol Exp Ther 337(3), 747–754, 2011.
   PubMed Web of Science ®Google Scholar
• Kim JM, Lee EK, Kim DH, Yu BP, and Chung HY: Kaempferol modulates pro-inflammatory NF-κB activation by suppressing advanced glycation endproducts-induced NADPH oxidase. Age 32(2), 197–208, 2010.
   PubMed Web of Science ®Google Scholar
• Park MJ, Lee EK, Heo H-S, Kim M-S, Sung B, et al.: The anti-inflammatory effect of kaempferol in aged kidney tissues: the involvement of nuclear factor-κ B via nuclear factor-inducing kinase/I κ B kinase and mitogen-activated protein kinase pathways. J Med Food 12(2), 351–358, 2009.
   PubMed Web of Science ®Google Scholar
• Acker DA, Kramer K, Grimbergen JA, Berg DJ, Vijgh WJ, et al.: Monohydroxyethylrutoside as protector against chronic doxorubicin‐induced cardiotoxicity. British J Pharmacol 115(7), 1260–1264, 1995.
   PubMed Web of Science ®Google Scholar
• van Acker FA, van Acker SA, Kramer K, Haenen GR, Bast A, et al.: 7-monohydroxyethylrutoside protects against chronic doxorubicin-induced cardiotoxicity when administered only once per week. Clin Cancer Res 6(4), 1337–1341, 2000.
   PubMed Web of Science ®Google Scholar
• Bruynzeel AM, Mul PP, Berkhof J, Bast A, Niessen HW, et al.: The influence of the time interval between monoHER and doxorubicin administration on the protection against doxorubicin-induced cardiotoxicity in mice. Cancer Chemoth Pharm 58(5), 699–702, 2006.
   PubMed Web of Science ®Google Scholar
• Bruynzeel AM, Vormer-Bonne S, Bast A, Niessen HW, and van der Vijgh WJ: Long-term effects of 7-monohydroxyethylrutoside (monoHER) on DOX-induced cardiotoxicity in mice. Cancer Chemoth Pharm 60(4), 509–514, 2007.
   PubMed Web of Science ®Google Scholar
• El Hassan MA, Verheul H, Jorna A, Schalkwijk C, Van Bezu J, et al.: The new cardioprotector monohydroxyethylrutoside protects against doxorubicin-induced inflammatory effects in vitro. British J Cancer 89(2), 357–362, 2003.
   PubMed Web of Science ®Google Scholar
• Bruynzeel AM, El Hassan MA, Schalkwijk C, Berkhof J, Bast A, et al.: Anti-inflammatory agents and monoHER protect against DOX-induced cardiotoxicity and accumulation of CML in mice. Br J Cancer 96(6), 937–943, 2007.
   PubMed Web of Science ®Google Scholar
• van Acker SA, Boven E, Kuiper K, van den Berg DJ, Grimbergen JA, et al.: Monohydroxyethylrutoside, a dose-dependent cardioprotective agent, does not affect the antitumor activity of doxorubicin. Clin Cancer Res 3(10), 1747–1754, 1997.
   PubMed Web of Science ®Google Scholar
• Willems AM, Bruynzeel AM, Kedde MA, Van Groeningen CJ, Bast A, et al.: A phase I study of monohydroxyethylrutoside in healthy volunteers. Cancer Chemother Pharmacol 57(5), 678–684, 2006.
   PubMed Web of Science ®Google Scholar
• Bruynzeel AM, Niessen HW, Bronzwaer JG, van der Hoeven JJ, Berkhof J, et al.: The effect of monohydroxyethylrutoside on doxorubicin-induced cardiotoxicity in patients treated for metastatic cancer in a phase II study. Br J Cancer 97(8), 1084–1089, 2007.
   PubMed Web of Science ®Google Scholar
• More SH, Sathe SB, Sonawane AA, Jadhav AP, and Kadam VJ: Estimation of naringin and hesperidin from citrus fruits by HPTLC. Am J Pharm Res 3(8), 6175–6183, 2013.
   Google Scholar
• Middleton Jr E and Kandaswami C: Effects of flavonoids on immune and inflammatory cell functions. Biochem Pharmacol 43(6), 1167–1179, 1992.
   PubMed Web of Science ®Google Scholar
• Kao Y-C, Zhou C, Sherman M, Laughton CA, and Chen S: Molecular basis of the inhibition of human aromatase (estrogen synthetase) by flavone and isoflavone phytoestrogens: a site-directed mutagenesis study. Environ Health Perspect 106(2), 85, 1998.
   PubMed Web of Science ®Google Scholar
• Guthrie N and Carroll K: Inhibition of mammary cancer by citrus flavonoids. In: Flavonoids in the Living System, Manthey J and Buslig B (eds.). New York: Springer, 1998, pp. 227–236.
   Google Scholar
• Jeon S-M, Park YB, and Choi M-S: Antihypercholesterolemic property of naringin alters plasma and tissue lipids, cholesterol-regulating enzymes, fecal sterol and tissue morphology in rabbits. Clin Nutr 23(5), 1025–1034, 2004.
   PubMed Web of Science ®Google Scholar
• Jagetia GC and Reddy TK: Alleviation of iron induced oxidative stress by the grape fruit flavanone naringin in vitro. Chem Biol Interact 190(2), 121–128, 2011.
   PubMed Web of Science ®Google Scholar
• Arafa HM, Abd-Ellah MF, and Hafez HF: Abatement by naringenin of doxorubicin-induced cardiac toxicity in rats. J Egypt Natl Canc Inst 17, 291–300, 2005.
   PubMedGoogle Scholar
• Jagetia GC and Reddy TK: The grape fruit flavonone naringin protects mice against doxorubicin-induced cardiotoxicity. J Mol Biochem 3(1), 34–49, 2014.
   Google Scholar
• Shiromwar SS and Chidrawar VR: Combined effects of p-coumaric acid and naringenin against doxorubicin-induced cardiotoxicity in rats. Pharmacognosy Res 3(3), 214, 2011.
   PubMedGoogle Scholar
• Han X, Ren D, Fan P, Shen T, and Lou H: Protective effects of naringenin-7-O-glucoside on doxorubicin-induced apoptosis in H9C2 cells. Eur J Pharma 581(1), 47–53, 2008.
   PubMed Web of Science ®Google Scholar
• Han X, Pan J, Ren D, Cheng Y, Fan P, et al.: Naringenin-7-O-glucoside protects against doxorubicin-induced toxicity in H9c2 cardiomyocytes by induction of endogenous antioxidant enzymes. Food Chem Toxicol 46(9), 3140–3146, 2008.
   PubMed Web of Science ®Google Scholar
• Cavin C, Marin-Kuan M, Langouët S, Bezençon C, Guignard G, et al.: Induction of Nrf2-mediated cellular defenses and alteration of phase I activities as mechanisms of chemoprotective effects of coffee in the liver. Food Chem Toxicol 46(4), 1239–1248, 2008.
   PubMed Web of Science ®Google Scholar
• Manandhar S, Cho J-M, Kim J, Kensler TW, and Kwak M-K: Induction of Nrf2-regulated genes by 3 H-1, 2-dithiole-3-thione through the ERK signaling pathway in murine keratinocytes. Eur J Pharmacol 577(1), 17–27, 2007.
   PubMed Web of Science ®Google Scholar
• Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, et al.: Nrf2 is a direct PERK substrate and effector of PERK-dependent cell survival. Mol Cell Biol 23(20), 7198–7209, 2003.
   PubMed Web of Science ®Google Scholar
• Sugden PH and Clerk A: Oxidative stress and growth-regulating intracellular signaling pathways in cardiac myocytes. Antioxid Redox Signal 8(11–12), 2111–2124, 2006.
   PubMed Web of Science ®Google Scholar
• Papasani VMR, Hanumantharayappa B, and Annapurna A: Cardioprotective effect of naringin against doxorubicin induced cardiomyopathy in rats. Indo Am J Pharma Res 4(5), 2593–2598, 2014.
   Google Scholar
• Chuang C-C, Martinez K, Xie G, Kennedy A, Bumrungpert A, et al.: Quercetin is equally or more effective than resveratrol in attenuating tumor necrosis factor-α–mediated inflammation and insulin resistance in primary human adipocytes. Am J Clin Nutr 92(6), 1511–1521, 2010.
   PubMed Web of Science ®Google Scholar
• Chen J-Y, Hu R-Y, and Chou H-C: Quercetin-induced cardioprotection against doxorubicin cytotoxicity. J Biomed Sci 20(1), 95, 2013.
   PubMed Web of Science ®Google Scholar
• Nazmi AS, Ahmad SJ, Pillai KK, Akhtar M, Ahmad A, et al.: Protective effects of Bombyx mori, quercetin and benazepril against doxorubicin induced cardiotoxicity and nephrotoxicity. J Saudi Chem Soc 2013.
   Google Scholar
• Matouk AI, Taye A, Heeba GH, and El-Moselhy MA: Quercetin augments the protective effect of losartan against chronic doxorubicin cardiotoxicity in rats. Environ Toxicol Pharmacol 36(2), 443–450, 2013.
   PubMed Web of Science ®Google Scholar
• Ismail IH, Andrin C, McDonald D, and Hendzel MJ: BMI1-mediated histone ubiquitylation promotes DNA double-strand break repair. J Cell Biol 191(1), 45–60, 2010.
   PubMed Web of Science ®Google Scholar
• Chatoo W, Abdouh M, David J, Champagne M-P, Ferreira J, et al.: The polycomb group gene Bmi1 regulates antioxidant defenses in neurons by repressing p53 pro-oxidant activity. J Neurosci 29(2), 529–542, 2009.
   PubMed Web of Science ®Google Scholar
• Dong Q, Chen L, Lu Q, Sharma S, Li L, et al.: Quercetin attenuates doxorubicin cardiotoxicity by modulating Bmi‐1 expression. Br J Pharmacol 171(19):4440–4454, 2014.
   PubMed Web of Science ®Google Scholar
• Pei TX, Xu CQ, Li B, Zhang ZR, Gao XX, et al.: Protective effect of quercetin against adriamycin-induced cardiotoxicity and its mechanism in mice. Yao Xue Xue Bao 42(10), 1029–1033, 2007.
   PubMedGoogle Scholar
• Atanassova M and Bagdassarian V: Rutin content in plant products. J Univers Chem Technol Metallurgy 44(2), 201–203, 2009.
   Google Scholar
• Hui CK, Mahdy ZA, Nordin NAMM, Ugusman A and Zakaria Z: Flavonoids of Piper sarmentosum and its cytoprotective effects against oxidative stress. Experiment Clin Sci Inter 11,705–714, 2012.
   Google Scholar
• Ugusman A, Zakaria Z, Chua KH, Megat Mohd Nordin NA, and Abdullah Mahdy Z: Role of rutin on nitric oxide synthesis in human umbilical vein endothelial cells. Sci World J, ID 169370, 2014.
   Web of Science ®Google Scholar
• Ashokkumar P and Sudhandiran G: Protective role of luteolin on the status of lipid peroxidation and antioxidant defense against azoxymethane-induced experimental colon carcinogenesis. Biomed Pharmacother 62(9), 590–597, 2008.
   PubMed Web of Science ®Google Scholar
• Nishitani Y, Yamamoto K, Yoshida M, Azuma T, Kanazawa K, et al.: Intestinal anti‐inflammatory activity of luteolin: role of the aglycone in NF‐κB inactivation in macrophages co‐cultured with intestinal epithelial cells. Biofactors 39(5), 522–533, 2013.
   PubMed Web of Science ®Google Scholar
• Xu T, Li D, and Jiang D: Targeting cell signaling and apoptotic pathways by luteolin: cardioprotective role in rat cardiomyocytes following ischemia/reperfusion. Nutrients 4(12), 2008–2019, 2012.
   PubMed Web of Science ®Google Scholar
• Salib JY, Michael HN, and Eskande EF: Anti-diabetic properties of flavonoid compounds isolated from Hyphaene thebaica epicarp on alloxan induced diabetic rats. Pharmacognosy Res 5(1), 22, 2013.
   PubMedGoogle Scholar
• Ashokkumar P and Sudhandiran G: Luteolin inhibits cell proliferation during Azoxymethane-induced experimental colon carcinogenesis via Wnt/β-catenin pathway. Invest New Drugs 29(2), 273–284, 2011.
   PubMed Web of Science ®Google Scholar
• Sadzuka Y, Sugiyama T, Shimoi K, Kinae N, and Hirota S: Protective effect of flavonoids on doxorubicin-induced cardiotoxicity. Toxicol Lett 92(1), 1–7, 1997.
   PubMed Web of Science ®Google Scholar
• Wang S-Q, Han X-Z, Li X, Ren D-M, Wang X-N, et al.: Flavonoids from Dracocephalum tanguticum and their cardioprotective effects against doxorubicin-induced toxicity in H9c2 cells. Bioorg Med Chem Lett 20(22), 6411–6415, 2010.
   PubMed Web of Science ®Google Scholar
• Manach C, Williamson G, Morand C, Scalbert A, and Rémésy C: Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. Am J Clin Nutr 81(1), 230S–242S, 2005.
   PubMed Web of Science ®Google Scholar
• Mullen W, Edwards CA, and Crozier A: Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl-and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions. Br J Nutr 96(01), 107–116, 2006.
   PubMed Web of Science ®Google Scholar
• Rupasinghe H, Ronalds CM, Rathgeber B, and Robinson RA: Absorption and tissue distribution of dietary quercetin and quercetin glycosides of apple skin in broiler chickens. J Sci Food Agric 90(7), 1172–1178, 2010.
   PubMed Web of Science ®Google Scholar
• Thilakarathna SH, Rupasinghe H, and Needs PW: Apple peel bioactive rich extracts effectively inhibit in vitro human LDL cholesterol oxidation. Food Chem 138(1), 463–470, 2013.
   PubMed Web of Science ®Google Scholar
• Panahi Y, Hosseini MS, Khalili N, Naimi E, Majeed M, et al.: Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: a randomized controlled trial and an updated meta-analysis. Clin Nutr 34(6) 1101–1108, 2015.
   PubMed Web of Science ®Google Scholar
• Panahi Y, Khalili N, Hosseini MS, Abbasinazari M, and Sahebkar A: Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. Complement Ther Med 22(5), 851–857, 2014.
   PubMed Web of Science ®Google Scholar
• Sahebkar A: Curcuminoids for the management of hypertriglyceridaemia. Nat Rev Cardiol 11(2), 123, 2014.
   PubMed Web of Science ®Google Scholar
• Sahebkar A: Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? Evidence from a meta-analysis. Phytother Res: PTR 28(5), 633–642, 2014.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Mohammadi A, Atabati A, Rahiman S, Tavallaie S, et al.: Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res: PTR 27(12), 1883–1888, 2013.
   PubMed Web of Science ®Google Scholar
• Sahebkar A: Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors 39(2), 197–208, 2013.
   PubMed Web of Science ®Google Scholar
• Mohammadi A, Sahebkar A, Iranshahi M, Amini M, Khojasteh R, et al.: Effects of supplementation with curcuminoids on dyslipidemia in obese patients: a randomized crossover trial. Phytother Res: PTR 27(3), 374–379, 2013.
   PubMed Web of Science ®Google Scholar
• Sahebkar A, Chew GT and Watts GF: Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res 56(47–66), 2014.
   PubMed Web of Science ®Google Scholar
• Venkatesan N: Curcumin attenuation of acute adriamycin myocardial toxicity in rats. Br J Pharmacol 124(3), 425–427, 1998.
   PubMed Web of Science ®Google Scholar
• Swamy AV, Gulliaya S, Thippeswamy A, Koti BC, and Manjula DV: Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol 44(1), 73–77, 2012.
   PubMed Web of Science ®Google Scholar
• Imbaby S, Ewais M, Essawy S, and Farag N: Cardioprotective effects of curcumin and nebivolol against doxorubicin-induced cardiac toxicity in rats. Hum Exp Toxicol 33(8), 800–813, 2014.
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami A, et al.: Curcumin potentiates doxorubicin-induced apoptosis in H9c2 cardiac muscle cells through generation of reactive oxygen species. Food Chem Toxicol 49(5), 1102–1109, 2011.
   PubMed Web of Science ®Google Scholar
• Hosseinzadeh L, Behravan J, Mosaffa F, Bahrami G, Bahrami A, et al.: Effect of curcumin on doxorubicin-induced cytotoxicity in H9c2 cardiomyoblast cells. Iranian J Basic Med Sci 14, 161, 2011.
   Web of Science ®Google Scholar
• Ribeiro N, Thuaud F, Nebigil C, and Désaubry L: Recent advances in the biology and chemistry of the flavaglines. Bioorg Med Chem 20(6), 1857–1864, 2012.
   PubMed Web of Science ®Google Scholar
• Ribeiro N, Thuaud F, Bernard Y, Gaiddon C, Cresteil T, et al.: Flavaglines as potent anticancer and cytoprotective agents. J Med Chem 55(22), 10064–10073, 2012.
   PubMed Web of Science ®Google Scholar
• Bernard Y, Ribeiro N, Thuaud F, Türkeri G, Dirr R, et al.: Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27. PLoS ONE 6(10), 2011.
   Web of Science ®Google Scholar
• Flora K, Hahn M, Rosen H, and Benner K: Milk thistle (Silybum marianum) for the therapy of liver disease. Am J Gastroenterol 93(2), 139–143, 1998.
   PubMed Web of Science ®Google Scholar
• Wellington K and Jarvis B: Silymarin: a review of its clinical properties in the management of hepatic disorders. BioDrugs 15(7), 465–489, 2001.
   PubMed Web of Science ®Google Scholar
• Dixit N, Baboota S, Kohli K, Ahmad S, and Ali J: Silymarin: a review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol 39(4), 172–179, 2007.
   Web of Science ®Google Scholar
• Psotová J, Chlopčíková Š, Grambal F, Šimánek V, and Ulrichová J: Influence of silymarin and its flavonolignans on doxorubicin‐iron induced lipid peroxidation in rat heart microsomes and mitochondria in comparison with quercetin. Phytother Res 16(S1), 63–67, 2002.
   PubMed Web of Science ®Google Scholar
• Makena PS, Pierce SC, Chung KT, and Sinclair SE: Comparative mutagenic effects of structurally similar flavonoids quercetin and taxifolin on tester strains Salmonella typhimurium TA102 and Escherichia coli WP‐2 uvrA. Environ Mol Mutagen 50(6), 451–459, 2009.
   PubMed Web of Science ®Google Scholar
• Chlopčíková Š, Psotová J, Miketová P, and Šimánek V: Chemoprotective effect of plant phenolics against anthracycline-induced toxicity on rat cardiomyocytes. Part I. Silymarin and its flavonolignans. Phytother Res 18(2), 107–110, 2004.
   PubMed Web of Science ®Google Scholar
• El-Shitany NA, El-Haggar S, and El-desoky K: Silymarin prevents adriamycin-induced cardiotoxicity and nephrotoxicity in rats. Food Chem Toxicol 46(7), 2422–2428, 2008.
   PubMed Web of Science ®Google Scholar
• Rašković A, Stilinović N, Kolarović J, Vasović V, Vukmirović S, et al.: The protective effects of silymarin against doxorubicin-induced cardiotoxicity and hepatotoxicity in rats. Molecules 16(10), 8601–8613, 2011.
   PubMed Web of Science ®Google Scholar
• Fouad AA and Yacoubi MT: Mechanisms underlying the protective effect of eugenol in rats with acute doxorubicin cardiotoxicity. Arch Pharm Res 34(5), 821–828, 2011.
   PubMed Web of Science ®Google Scholar
• Fadillioglu E, Oztas E, Erdogan H, Yagmurca M, Sogut S, et al.: Protective effects of caffeic acid phenethyl ester on doxorubicin-induced cardiotoxicity in rats. J Appl Toxicol 24(1), 47–52, 2004.
   PubMed Web of Science ®Google Scholar
• Kim DS, Woo ER, Chae SW, Ha KC, Lee GH, et al.: Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-κB activation. Life Sci 80(4), 314–323, 2007.
   PubMed Web of Science ®Google Scholar
• Russo A, Longo R, and Vanella A: Antioxidant activity of propolis: role of caffeic acid phenethyl ester and galangin. Fitoterapia 73, S21–S29, 2002.
   PubMed Web of Science ®Google Scholar
• Wang X-L, Wang X, Xiong L-L, Zhu Yc, Chen H-L, Chen J-X, et al.: Salidroside improves doxorubicin-induced cardiac dysfunction by suppression of excessive oxidative stress and cardiomyocyte apoptosis. J Cardiovasc Pharmacol 62, 512–523, 2013.
   PubMed Web of Science ®Google Scholar
• Granados-Principal S, Quiles JL, Ramirez-Tortosa CL, Sanchez-Rovira P, and Ramirez-Tortosa MC: Hydroxytyrosol: from laboratory investigations to future clinical trials. Nutr Rev 68(4), 191–206, 2010.
   PubMed Web of Science ®Google Scholar
• Granados-Principal S, El-Azem N, Pamplona R, Ramirez-Tortosa C, Pulido-Moran M, et al.: Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in doxorubicin-induced cardiotoxicity in rats with breast cancer. Biochem Pharmacol 90(1), 25–33, 2014.
   PubMed Web of Science ®Google Scholar
• Andreadou I, Sigala F, Iliodromitis EK, Papaefthimiou M, Sigalas C, et al.: Acute doxorubicin cardiotoxicity is successfully treated with the phytochemical oleuropein through suppression of oxidative and nitrosative stress. J Mol Cell Cardiol 42(3), 549–558, 2007.
   PubMed Web of Science ®Google Scholar
• Andreadou I, Papaefthimiou M, Zira A, Constantinou M, Sigala F, et al.: Metabonomic identification of novel biomarkers in doxorubicin cardiotoxicity and protective effect of the natural antioxidant oleuropein. NMR Biomed 22(6), 585–592, 2009.
   PubMed Web of Science ®Google Scholar
• Kim M and Tian R: Targeting AMPK for cardiac protection: opportunities and challenges. J Mol Cell Cardiol 51(4), 548–553, 2011.
   PubMed Web of Science ®Google Scholar
• Menendez JA, Joven J, Aragones G, Barrajon-Catalan E, Beltran-Debon R, et al.: Xenohormetic and anti-aging activity of secoiridoid polyphenols present in extra virgin olive oil: a new family of gerosuppressant agents. Cell Cycle 12(4), 555–578, 2013.
   PubMed Web of Science ®Google Scholar
• Andreadou I, Mikros E, Ioannidis K, Sigala F, Naka K, et al.: Oleuropein prevents doxorubicin-induced cardiomyopathy interfering with signaling molecules and cardiomyocyte metabolism. J Mol Cell Cardiol 69, 4–16, 2014.
   PubMed Web of Science ®Google Scholar
• Pangeni R, Sahni JK, Ali J, Sharma S, and Baboota S: Resveratrol: review on therapeutic potential and recent advances in drug delivery. Expert Opin Drug Del 11(8), 1285–1298, 2014.
   PubMed Web of Science ®Google Scholar
• Brookins Danz ED, Skramsted J, Henry N, Bennett JA, and Keller RS: Resveratrol prevents doxorubicin cardiotoxicity through mitochondrial stabilization and the Sirt1 pathway. Free Radic Biol Med 46(12), 1589–1597, 2009.
   PubMed Web of Science ®Google Scholar
• Tatlidede E, Şehirli Ö, Velioglu-Ögüç A, Çetinel S, Yegen BÇ, et al.: Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 43(3), 195–205, 2009.
   PubMed Web of Science ®Google Scholar
• Zhang C, Feng Y, Qu S, Wei X, Zhu H, et al.: Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in mice through SIRT1-mediated deacetylation of p53. Cardiovasc Res 90(3), 538–545, 2011.
   PubMed Web of Science ®Google Scholar
• Pinarli FA, Turan NN, Pinarli FG, Okur A, Sönmez D, et al.: Resveratrol and adipose-derived mesenchymal stem cells are effective in the prevention and treatment of doxorubicin cardiotoxicity in rats. Pediatr Hematol Oncol 30(3), 226–238, 2013.
   PubMed Web of Science ®Google Scholar
• Cao Z and Li Y: Potent induction of cellular antioxidants and phase 2 enzymes by resveratrol in cardiomyocytes: protection against oxidative and electrophilic injury. Eur J Pharmacol 489(1–2), 39–48, 2004.
   PubMed Web of Science ®Google Scholar
• Beher D, Wu J, Cumine S, Kim KW, Lu S-C, et al.: Resveratrol is not a direct activator of SIRT1 enzyme activity. Chem Biol Drug Des 74(6), 619–624, 2009.
   PubMed Web of Science ®Google Scholar
• Dirks-Naylor AJ: The role of autophagy in doxorubicin-induced cardiotoxicity. Life Sci 93(24), 913–916, 2013.
   PubMed Web of Science ®Google Scholar
• Xu X, Chen K, Kobayashi S, Timm D, and Liang Q: Resveratrol attenuates doxorubicin-induced cardiomyocyte death via inhibition of p70 S6 kinase 1-mediated autophagy. J Pharmacol Exp Ther 341(1), 183–195, 2012.
   PubMed Web of Science ®Google Scholar
• Wenzel E and Somoza V: Metabolism and bioavailability of trans-resveratrol. Mol Nutr Food Res 49(5), 472–481, 2005.
   PubMed Web of Science ®Google Scholar
• Gu J, Song ZP, Gui DM, Hu W, Chen YG, et al.: Resveratrol attenuates doxorubicin-induced cardiomyocyte apoptosis in lymphoma nude mice by heme oxygenase-1 induction. Cardiovasc Toxicol 12(4), 341–349, 2012.
   PubMed Web of Science ®Google Scholar
• Arafa MH, Mohammad NS, Atteia HH, and Abd-Elaziz HR: Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J Physiol Biochem 70(3), 701–711, 2014.
   PubMed Web of Science ®Google Scholar
• Bernuzzi F, Recalcati S, Alberghini A, and Cairo G: Reactive oxygen species-independent apoptosis in doxorubicin-treated H9c2 cardiomyocytes: role for heme oxygenase-1 down-modulation. Chem Biol Interact 177(1), 12–20, 2009.
   PubMed Web of Science ®Google Scholar
• Díaz-Chávez J, Fonseca-Sánchez MA, Arechaga-Ocampo E, Flores-Pérez A, Palacios-Rodríguez Y, et al.: Proteomic profiling reveals that resveratrol inhibits HSP27 expression and sensitizes breast cancer cells to doxorubicin therapy. PLoS ONE 8(5), e64378, 2013.
   PubMed Web of Science ®Google Scholar
• Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, et al.: Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin. Biochim Biophys Acta 1840(1), 615–625, 2014.
   PubMed Web of Science ®Google Scholar
• Osman AM, Al-Harthi SE, AlArabi OM, Elshal MF, Ramadan WS, et al.: Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin-treated animals. Cancer Cell Int 13(52), 2013.
   PubMed Web of Science ®Google Scholar
• Carlson LJ, Cote B, Alani AW, and Rao DA: Polymeric micellar co-delivery of resveratrol and curcumin to mitigate in vitro doxorubicin-induced cardiotoxicity. J Pharm Sci 103(8):2315–2322, 2014.
   PubMed Web of Science ®Google Scholar
• Zhang SH, Wang WQ, and Wang JL: Protective effect of tetrahydroxystilbene glucoside on cardiotoxicity induced by doxorubicin in vitro and in vivo. Acta Pharmacol Sin 30(11), 1479–1487, 2009.
   PubMed Web of Science ®Google Scholar
• Nayak PG, Paul P, Bansal P, Kutty NG, and Pai KS: Sesamol prevents doxorubicin-induced oxidative damage and toxicity on H9c2 cardiomyoblasts. J Pharm Pharmacol 65(7), 1083–1093, 2013.
   PubMed Web of Science ®Google Scholar
• Chennuru A and Saleem MT: Antioxidant, lipid lowering, and membrane stabilization effect of sesamol against doxorubicin-induced cardiomyopathy in experimental rats. Biomed Res Int 2013, 934239, 2013.
   PubMed Web of Science ®Google Scholar
• Liang Y: Clinical study on “sini” decoction on treating stenocardia for coronary heart disease. Zhong Yao Cai 28(8), 737–739, 2005.
   PubMedGoogle Scholar
• Chen YL, Zhuang XD, Xu ZW, Lu LH, Guo HL, et al.: Higenamine combined with [6]-gingerol suppresses doxorubicin-triggered oxidative stress and apoptosis in cardiomyocytes via upregulation of PI3K/Akt pathway. Evid Based Complement Alternat Med 2013, 970490, 2013.
   PubMed Web of Science ®Google Scholar
• El-Bakly WM, Louka ML, El-Halawany AM, and Schaalan MF: 6-gingerol ameliorated doxorubicin-induced cardiotoxicity: role of nuclear factor kappa B and protein glycation. Cancer Chemother Pharmacol 70(6), 833–841, 2012.
   PubMed Web of Science ®Google Scholar
• Balasundram N, Sundram K, and Samman S: Phenolic compounds in plants and agri-industrial by-products: antioxidant activity, occurrence, and potential uses. Food Chem 99(1), 191–203, 2006.
   Web of Science ®Google Scholar
• Michalak A: Phenolic compounds and their antioxidant activity in plants growing under heavy metal stress. Pol J Environl Stud 15(4), 523, 2006.
   Web of Science ®Google Scholar
• Milić BL, Djilas SM, and Čanadanović-Brunet JM: Antioxidative activity of phenolic compounds on the metal-ion breakdown of lipid peroxidation system. Food Chem 61(4), 443–447, 1998.
   Web of Science ®Google Scholar
• Camello-Almaraz C, Gomez-Pinilla PJ, Pozo MJ, and Camello PJ: Mitochondrial reactive oxygen species and Ca2+ signaling. Am J Physiol-Cell Physiol 291(5), C1082–C1088, 2006.
   PubMed Web of Science ®Google Scholar
• Gen W, Tani M, Takeshita J, Ebihara Y, and Tamaki K: Mechanisms of Ca2+ overload induced by extracellular H2O2 in quiescent isolated rat cardiomyocytes. Basic Res Cardiol 96(6), 623–629, 2001.
   PubMed Web of Science ®Google Scholar
• Zeng Q, Zhou Q, Yao F, O'Rourke ST, and Sun C: Endothelin-1 regulates cardiac L-type calcium channels via NAD (P) H oxidase-derived superoxide. J Pharmacol Exp Ther 326(3), 732–738, 2008.
   PubMed Web of Science ®Google Scholar
• Zhang Y-W, Shi J, Li Y-J, and Wei L: Cardiomyocyte death in doxorubicin-induced cardiotoxicity. Arch Immunol Ther Exp 57(6), 435–445, 2009.
   PubMed Web of Science ®Google Scholar
• Kim D-S, Woo E-R, Chae S-W, Ha K-C, Lee G-H, et al.: Plantainoside D protects adriamycin-induced apoptosis in H9c2 cardiac muscle cells via the inhibition of ROS generation and NF-κB activation. Life Sci 80(4), 314–323, 2007.
   PubMed Web of Science ®Google Scholar
• Li H, Gu H, and Sun B: Protective effects of pyrrolidine dithiocarbamate on myocardium apoptosis induced by adriamycin in rats. Int J Cardiol 114(2), 159–165, 2007.
   PubMed Web of Science ®Google Scholar
• Velderrain-Rodríguez G, Palafox-Carlos H, Wall-Medrano A, Ayala-Zavala J, Chen CO, et al.: Phenolic compounds: their journey after intake. Food Funct 5(2), 189–197, 2014.
   PubMed Web of Science ®Google Scholar
• Rubio L, Macia A, and Motilva M-J: Impact of various factors on pharmacokinetics of bioactive polyphenols: an overview. Curr Drug Metab 15(1), 62–76, 2014.
   PubMed Web of Science ®Google Scholar
• Li Z, Jiang H, Xu C and Gu L: A review: using nanoparticles to enhance absorption and bioavailability of phenolic phytochemicals. Food Hydrocoll 43, 153–164, 2015.
   Web of Science ®Google Scholar